Quest Diagnostics Incorporated’s Stock Price Drops to $168.01, Witnessing a 2.57% Decline

Quest Diagnostics Incorporated (DGX)

168.01 USD -4.44 (-2.57%) Volume: 1.6M

Quest Diagnostics Incorporated’s stock price stands at 168.01 USD, experiencing a dip of -2.57% this trading session, with a trading volume reaching 1.6M. Despite the slight setback, DGX’s stock maintains a robust growth of +11.37% YTD, highlighting its strong market presence and potential for investors.

Latest developments on Quest Diagnostics Incorporated

Quest Diagnostics recently unveiled their ambitious growth strategy at their Investor Day, outlining five key areas that are set to drive double-digit expansion beyond 2025. The company has reaffirmed their 2025 guidance, projecting steady growth in the coming years. Quest Diagnostics has also announced a strategic partnership with Google Cloud to streamline data management and personalize customer experiences using generative AI. Despite a slight stock fall due to Q1 headwinds and long-term guidance concerns, Quest Diagnostics remains focused on driving sustainable growth and delivering long-term shareholder value through their innovative collaborations and growth strategies.

Quest Diagnostics Incorporated on Smartkarma

Analysts at Baptista Research have provided bullish coverage on Quest Diagnostics, highlighting the company’s strong financial performance driven by revenue growth from acquisitions and organic sources. In their report titled “Quest Diagnostics: Enhanced Offerings In Cardiometabolic Testing & Autoimmune Disorders Catalyzing Growth!”, they noted a 14.5% increase in revenue for the fourth quarter of 2024, with organic revenue growth contributing nearly 5%. The completion of eight acquisitions, including LifeLabs in Canada, has strengthened Quest Diagnostics‘ market position and expanded its geographic reach within the physician and hospital channels.

Furthermore, Baptista Research‘s analysis in “Quest Diagnostics: Expansion into New Markets through Strategic Acquisitions As A Critical Growth Catalyst! – Major Drivers” underscores the company’s robust performance in the third quarter, with a total revenue growth of 8.5% and 4.2% organic growth. Strategic initiatives such as new customer acquisitions, expanding business with existing customers, and key acquisitions like LifeLabs have been pivotal in driving growth and scaling operations in both Canada and the U.S. market for Quest Diagnostics.

A look at Quest Diagnostics Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Quest Diagnostics seems to have a positive long-term outlook. With a high score in Momentum, the company is showing strong growth potential and market performance. Additionally, Quest Diagnostics scores well in Dividend, indicating a stable financial position and potential for returns for investors. However, the company scores lower in Resilience, suggesting some vulnerability to market fluctuations.

Quest Diagnostics, a company that provides diagnostic testing and services, receives moderate scores in Value and Growth. This indicates that while the company may not be undervalued, it still has room for potential growth. Overall, with a mix of scores across different factors, Quest Diagnostics appears to be a solid investment option for those looking for steady returns and potential growth in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma